| Aquaporin-4-dependent glymphatic solute transport in the rodent brain H Mestre, LM Hablitz, ALR Xavier, W Feng, W Zou, T Pu, H Monai, ... Elife 7, e40070, 2018 | 464 | 2018 |
| Biology of adeno-associated viral vectors in the central nervous system G Murlidharan, RJ Samulski, A Asokan Frontiers in molecular neuroscience 7, 76, 2014 | 203 | 2014 |
| Mapping the structural determinants required for AAVrh. 10 transport across the blood-brain barrier BH Albright, CM Storey, G Murlidharan, RMC Rivera, GE Berry, ... Molecular Therapy 26 (2), 510-523, 2018 | 85 | 2018 |
| Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain G Murlidharan, A Crowther, RA Reardon, J Song, A Asokan JCI insight 1 (14), 2016 | 83 | 2016 |
| CNS-restricted transduction and CRISPR/Cas9-mediated gene deletion with an engineered AAV vector G Murlidharan, K Sakamoto, L Rao, T Corriher, D Wang, G Gao, ... Molecular Therapy-Nucleic Acids 5, 2016 | 75 | 2016 |
| AAV gene therapy for MPS1-associated corneal blindness M Vance, T Llanga, W Bennett, K Woodard, G Murlidharan, N Chungfat, ... Scientific reports 6 (1), 22131, 2016 | 56 | 2016 |
| Unique glycan signatures regulate adeno-associated virus tropism in the developing brain G Murlidharan, T Corriher, HT Ghashghaei, A Asokan Journal of virology 89 (7), 3976-3987, 2015 | 44 | 2015 |
| The Golgi calcium ATPase pump plays an essential role in adeno-associated virus trafficking and transduction VJ Madigan, GE Berry, TO Tyson, D Nardone-White, J Ark, ZC Elmore, ... Journal of virology 94 (21), 10.1128/jvi. 01604-20, 2020 | 17 | 2020 |
| Aquaporin-4-dependent glymphatic solute transport in the rodent brain. eLife 7 H Mestre, LM Hablitz, AL Xavier, W Feng, W Zou, T Pu, H Monai, ... | 13 | 2018 |
| 30. Modulation of intracellular calcium enhances AAV transduction in the CNS G Berry, G Murlidharan, A Asokan Molecular Therapy 24, S14, 2016 | 8 | 2016 |
| Compositions and methods for delivery of aav DWY Sah, H Patzke, T Carter, J Hou, G Murlidharan US Patent App. 17/055,416, 2021 | 5 | 2021 |
| Methods and compositions for targeted gene transfer A Asokan, G Murlidharan, S Shen US Patent 10,907,176, 2021 | 5 | 2021 |
| Compositions and methods for delivery of aav G Murlidharan, DWY Sah, H Patzke, T Carter, J Hou, K Adachi, A Ren US Patent App. 17/284,499, 2021 | 2 | 2021 |
| 55. Aquaporins and CSF flux are critical determinants of AAV mediated CNS gene Transfer G Murlidharan, A Asokan Molecular Therapy 24, S25, 2016 | 2 | 2016 |
| Efficacy of a vectorized anti‐tau antibody using systemic dosing of a blood brain barrier penetrant AAV capsid in mouse models of tauopathies W Liu, J Holth, M Paranjpe, XQ Ren, Y Shu, G Murlidharan, C Chung, ... Alzheimer's & Dementia 17, e053341, 2021 | 1 | 2021 |
| AAV gene delivery of an anti-Tau antibody using a novel blood brain barrier penetrant capsid in wild type and P301S tauopathy mice TA Carter, W Liu, G Murlidharan, Y Shu, M Paranjpe, C Huang, ... HUMAN GENE THERAPY 28 (12), A80-A80, 2017 | 1 | 2017 |
| Discovery of a Neurotropic Footprint That Enables AAV Transport Across the Blood-Brain Barrier B Albright, C Storey, G Murlidharan, RC Rivera, A Asokan MOLECULAR THERAPY 25 (5), 230-231, 2017 | 1 | 2017 |
| 14. Next Generation AAV Vectors for Limiting Systemic Leakage and Improving Safety Following CNS Administration G Murlidharan, L Rao, D Wang, T Corriher, K Seok-Oh, G Gao, ... Molecular Therapy 23, S6, 2015 | 1 | 2015 |
| 42. Differential transduction profiles of AAV vectors in a mouse model of human glycosylation L Rao, BH Albright, T Corriher, G Murlidharan, A Asokan Molecular Therapy 23, S18-S19, 2015 | 1 | 2015 |
| Compositions for and methods of improving fluid flux in the brain A Asokan, A Mitchell-Dick, G Murlidharan, RC Rivera US Patent App. 18/272,208, 2024 | | 2024 |
![Giridhar Murlidharan [Giri]](/citations/images/avatar_scholar_128.png)